Expanded Urine Toxicology Panel (Pain Management Drug Testing Panel)
Label Mnemonic: | EXTOXU |
Epic code: | LAB8951 |
Downtime form: | Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Urine
Collection Medium:
Minimum:
Preferred Minimum: 4 mL each into TWO (2) Yellow top
tubes with no additives or preservatives
Absolute Minimum: 2 mL each into TWO (2) Yellow top tubes with no additives or preservatives
Absolute Minimum: 2 mL each into TWO (2) Yellow top tubes with no additives or preservatives
Rejection Criteria:
Specimens exposed to repeated freeze/thaw cycles.
Turn Around
Time:
1-3 days upon receipt at reference laboratory
Reference Range:
Effective February 16, 2021 Drugs covered and range of cutoff concentrations. Note: some drugs are identified based on the presence of unique drug metabolites not listed below. Drugs/Drug Classes Range of Cutoff Concentrations Barbiturates 200 ng/mL Benzodiazepine-like: alprazolam, clonazepam, 20-60 ng/mL diazepam, lorazepam, midazolam, nordiazepam, oxazepam, temazepam, zolpidem Cannabinoids (11-nor-9-carboxy-THC) 20 ng/mL Ethyl Glucuronide 500 ng/mL Muscle Relaxant(s): carisoprodol, meprobamate 100 ng/mL Opiates/Opioids: buprenorphine, codeine, fentanyl, 2-300 ng/mL heroin, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, tapentadol, tramadol GABA analogues: 100 ng/mL Gabapentin, pregabalin Phencyclidine (PCP) 25 ng/mL Stimulants: amphetamine, cocaine, methamphetamine, 50-400 ng/mL methylphenidate, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
Interpretive Data:
The absence of expected drug(s) and/or drug metabolite(s) may indicate noncompliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff concentration to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request confirmation and quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.
For medical purposes only; not valid for forensic use.
Comments:
This test is known as Pain Management Drug Testing Panel (LAB8349) in specific order sets in Epic.
Note: Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Note: Creatinine concentration is also provided. The carisoprodol immunoassay has cross-reactivity to carisoprodol and meprobamate.
Methodology:
Qualitative Liquid Chromatography-Tandem Mass Spectrometry/Enzyme Immunoassay/Quantitative Spectrophotometry
CPT Code:
80307x5
See Additional Information:
Urine Tests Requiring no Preservatives
Urine Tests Requiring no Preservatives